Jan Burger, MD, PhD, Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, discusses an analysis of the RESONATE-2 and iLLUMINATE studies, which explored outcomes of first-line ibrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and high-risk genomic features.
These results were presented at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Listen to the original podcast on Oncology Learning Network.
